All PlansCoverageMedium impact
Recall: Anagrelide
UPMC Health Plan·PA · Hematology, Internal Medicine, Pharmacy +1 more·Pharmacy
Effective date
Jun 1, 2022
We identified it
Aug 7, 2026
Summary
Teva has issued a recall for one lot of Anagrelide 0.5 mg capsules due to dissolution rate issues that may affect drug efficacy in patients with elevated platelet counts. Billing teams must be aware that affected prescriptions may require rebilling, alternative medication substitution, or patient communication regarding the recall.
Action Required
Immediately: Billing and clinical teams must coordinate to identify any claims or prescriptions containing the recalled Anagrelide 0.5 mg lot. Contact affected patients and providers to determine if alternative medications (such as other thrombocytosis agents) need to be prescribed and billed instead. Flag any pending or recently processed claims for this medication lot in the billing system for potential reversal or adjustment. Monitor for patient inquiries and coordinate with pharmacy to ensure continuity of care with non-recalled inventory or alternative therapies. Document all recall-related communications and claim adjustments for compliance records.